Search

everythinglearnresearchcommunity

for

Search:↓

A six month update of the users' experience with Pyrilutamide, a hair loss treatment that combines Minoxidil, Finasteride and RU58841.

A user discusses an Iranian hair loss treatment brought by their mom, questioning its effectiveness. Replies mention that Kopexil, an ingredient in the product, is different from Minoxidil and less tested.

The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.

The conversation discusses the potential of a new hair loss treatment, GT20029, which may prevent hair loss by destroying androgen receptors on the scalp. Users express hope for the treatment's success and speculate on its usage routine, effectiveness, and possible side effects.

The conversation is about comparing hair loss treatments Pyrilutamide (KX-826) and CB-03-01, discussing their cost, side effects, and effectiveness. The user questions whether to try CB-03-01, which is more expensive and potentially less effective, or switch to the cheaper and possibly better Pyrilutamide.

Comparing the effectiveness of RU58841, Pyrilutamide and CB-03-01 as treatments for hair loss, with people discussing different aspects such as binding affinity, time of inhibition, safety data and cost.

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

Hair loss discussion includes treatments Minoxidil, Finasteride, and RU58841. User seeks updates on topical treatment Pyrilutamide.

Kintor Pharmaceutical's stock rise suggests potential positive news about Pyrilutamide, a topical anti-androgen. GT20029 may also compete with existing treatments like finasteride and dutasteride.

The conversation discusses the potential release date of a hair loss treatment called Pyrilutamide. One user suggests it may be available in about 5 years.

The results of using Pyrilutamide, a hair loss treatment available on the gray market, and other treatments such as Minoxidil, Finasteride and RU58841.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

Automatic-Law-3612's progress with hair loss treatments, including topical finasteride, topical dutasteride, minoxidil and pyrilutamide. They have been using these products for two weeks and noticed baby hairs in their temples getting longer.

The conversation discusses using topical Minoxidil and Finasteride from Traya, along with daily dermarolling, as a treatment for hair loss. Progress pictures were shared to show the results of these treatments.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

Pyrilutamide is discussed as a potential hair loss treatment, acting as an androgen receptor antagonist. The conversation questions if it can maintain hair long-term without using finasteride.

Hair loss discussion includes Minoxidil, Finasteride, and RU58841 treatments. Pyrilutamide cleared for phase 3 clinical trial in China.

User ronopibf discusses Fagron TrichoTest, a genetic test for hair loss, and seeks opinions on its effectiveness. Some users support the service, while others call it a scam, with prices ranging from $200-$500.

Hair loss treatments like minoxidil, finasteride, and dutasteride can stabilize hair loss and sometimes regrow hair, but many people still opt for hair transplants, often in Turkey, due to cost and convenience. However, transplants require ongoing medication to maintain results, and not all clinics offer high-quality outcomes.

A user is experiencing hairline recession and has started using RU58841, applying it to the temples. They are seeking advice on the appropriate dosage for this specific area.

The discussion is about a hair loss drug called pyrilutamide. Users discuss its efficacy, safety, and expected market release around 2025-2026, with some expressing concerns about the authenticity of current market offerings.

User asks if Kintor, HMI-115, or Olix will release hair loss drugs in 2023. Conversation discusses potential treatments and release dates.

First patient dosed with Pyrilutamide (Kintor) Phase III for hair loss treatment. Pyrilutamide differs from approved treatments as it competes with DHT to bind hair follicles, potentially reducing side effects.

The conversation introduces a specialized chatbot for ChatGPT Plus users that provides advice on hair loss treatments, drawing from research and community insights. It mentions treatments like RU58841, the "big 4" (likely minoxidil, finasteride, ketoconazole, and tretinoin), dutasteride mesotherapy, topical melatonin, microneedling, and rapamycin.

The post discusses the user's experience with hair loss treatment RU58841, which was tested for quality and found to be 96+% pure. The conversation includes various responses, with some users questioning the safety of the product and others expressing satisfaction with the test results.

The conversation is about finding alfatradiol in the US for hair loss treatment. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.

Piroctone olamine may be more effective and gentler than ketoconazole for dandruff and itchiness. Users report better results with piroctone olamine, but it is less available in the US.

The conversation is about obtaining alfatradiol in Canada, specifically in Quebec, and whether it requires a prescription or can be bought online. A user suggests ordering it from a specific website.

SCUBE3 clinical trials for hair loss treatment to start this year. Treatment may involve regular, painless scalp injections to maintain hair growth.

Pyrilutamide (KX826) sourcing and pricing, with users discussing the legitimacy and cost of grey market versus official sources. The conversation highlights the high cost of official products and the effectiveness of grey market versions.